Dairong Li1, Chunyan Zhang2, Nan Lu3, Liuqing Mu2, Yonglin He2, Lei Xu2, Jing Yang2, Yu Fan2, Yuexi Kang2, Chun Yang2. 1. Department of Respiratory Disease, The First Affiliated Hospital of Chongqing Medical University Chongqing 400016, China ; Department of Pathology, Chongqing Medical University Chongqing 400016, China. 2. Department of Pathogenic Organisms, Chongqing Medical University Chongqing 400016, China ; Molecular Medicine and Cancer Research Center, Chongqing Medical University Chongqing 400016, China. 3. Molecular Medicine and Cancer Research Center, Chongqing Medical University Chongqing 400016, China.
Abstract
OBJECTIVE: To clone, express, and characterize Mycobacterium tuberculosis (Mtb) ClpP2, and evaluated the potential usage of ClpP2 in clinical diagnosis of tuberculosis. METHODS: Mtb ClpP2 was cloned into recombinant plasmid pET32a (+) and transformed into E. coli BL21 (DE3). SDS-PAGE and Western blot analysis were performed to detect the expression of the recombinant protein. The immunogenicity of Mtb ClpP2 was assessed with epitope prediction and antibody titer assay. Quantitative real-time PCR was performed to detect the influence of stress conditions on ClpP2 expression. ClpP2 antigen and antibody in patients with pulmonary diseases were detected by indirect ELISA. ROC curve was constructed to assess the diagnostic accuracy of Mtb ClpP2 for tuberculosis. RESULTS: We had cloned and expressed recombinant Mtb ClpP2 in E. coli. Our results showed that Mtb ClpP2 had potent immunogenicity, and our own prepared polyclonal antibody could be used in detection and diagnostic tests. Results from Western blot showed that ClpP2 was mainly located in M. bovis BCG cytoplasm, and real-time PCR indicated that stress conditions could enhance the mRNA expression of ClpP2. Indirect ELISA suggested that, in tuberculosis patients, both the levels of ClpP2 antigen and antibody were increased, and the positive rates of ClpP2 were elevated. ROC curve had demonstrated satisfactory sensitivity and specificity of ClpP2-based diagnosis for tuberculosis. CONCLUSION: Our results suggest that Mtb ClpP2 antigens would be used as a biomarker in tuberculosis pathogenesis. These findings highlight the feasibility of the application of Mtb ClpP2 in the clinical diagnosis of tuberculosis.
OBJECTIVE: To clone, express, and characterize Mycobacterium tuberculosis (Mtb) ClpP2, and evaluated the potential usage of ClpP2 in clinical diagnosis of tuberculosis. METHODS:MtbClpP2 was cloned into recombinant plasmid pET32a (+) and transformed into E. coli BL21 (DE3). SDS-PAGE and Western blot analysis were performed to detect the expression of the recombinant protein. The immunogenicity of MtbClpP2 was assessed with epitope prediction and antibody titer assay. Quantitative real-time PCR was performed to detect the influence of stress conditions on ClpP2 expression. ClpP2 antigen and antibody in patients with pulmonary diseases were detected by indirect ELISA. ROC curve was constructed to assess the diagnostic accuracy of MtbClpP2 for tuberculosis. RESULTS: We had cloned and expressed recombinant MtbClpP2 in E. coli. Our results showed that MtbClpP2 had potent immunogenicity, and our own prepared polyclonal antibody could be used in detection and diagnostic tests. Results from Western blot showed that ClpP2 was mainly located in M. bovis BCG cytoplasm, and real-time PCR indicated that stress conditions could enhance the mRNA expression of ClpP2. Indirect ELISA suggested that, in tuberculosispatients, both the levels of ClpP2 antigen and antibody were increased, and the positive rates of ClpP2 were elevated. ROC curve had demonstrated satisfactory sensitivity and specificity of ClpP2-based diagnosis for tuberculosis. CONCLUSION: Our results suggest that MtbClpP2 antigens would be used as a biomarker in tuberculosis pathogenesis. These findings highlight the feasibility of the application of MtbClpP2 in the clinical diagnosis of tuberculosis.
Authors: Tatos Akopian; Olga Kandror; Ravikiran M Raju; Meera Unnikrishnan; Eric J Rubin; Alfred L Goldberg Journal: EMBO J Date: 2012-01-27 Impact factor: 11.598
Authors: Amit Kaushik; Urvashi B Singh; Chhavi Porwal; Shwetha J Venugopal; Anant Mohan; Anand Krishnan; Vinay Goyal; Jayant N Banavaliker Journal: Indian J Med Res Date: 2012-05 Impact factor: 2.375
Authors: Susmita Sarkar; Xinli L Tang; Dipankar Das; John S Spencer; Todd L Lowary; Mavanur R Suresh Journal: PLoS One Date: 2012-02-21 Impact factor: 3.240
Authors: Ravikiran M Raju; Meera Unnikrishnan; Daniel H F Rubin; Vidhya Krishnamoorthy; Olga Kandror; Tatos N Akopian; Alfred L Goldberg; Eric J Rubin Journal: PLoS Pathog Date: 2012-02-16 Impact factor: 6.823